The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.

ABSTRACT:

SUBMITTER: Banerjee SN 

PROVIDER: S-EPMC12758252 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature